Literature DB >> 31399969

Myofibroblast in Kidney Fibrosis: Origin, Activation, and Regulation.

Qian Yuan1, Roderick J Tan2, Youhua Liu3,4.   

Abstract

Renal fibrosis is characterized by excessive deposition of extracellular matrix (ECM), leading to destruction of normal kidney architecture and loss of renal function. The activation of α-smooth muscle actin-positive myofibroblasts plays a key role in this process. After kidney injury, profibrotic factors are secreted by injured tubular epithelia and infiltrated inflammatory cells to promote complex cascades of signaling events leading to myofibroblastic activation, proliferation, and ECM production. The origins of myofibroblasts remain controversial, and possibilities include resident fibroblasts, pericytes, bone marrow-derived cells, and endothelial cells. Recent evidence supports the existence of localized fibrogenic niches, which provides a specialized tissue microenvironment for myofibroblastic activation and expansion. Myofibroblasts often undergo epigenetic modifications, leading to their sustained activation and resistance to apoptosis. In this chapter, we discuss the origins, heterogeneity, and activation of myofibroblasts in diseased kidneys. We also highlight novel strategies for the treatment of patients with fibrotic kidney diseases.

Entities:  

Keywords:  EMT; Fibrotic niche; Myofibroblast; Renal fibrosis; Wnt signaling

Mesh:

Year:  2019        PMID: 31399969     DOI: 10.1007/978-981-13-8871-2_12

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  32 in total

1.  Value of [68Ga]Ga-FAPI-04 imaging in the diagnosis of renal fibrosis.

Authors:  Yue Zhou; Xin Yang; Huipan Liu; Wenbin Luo; Hanxiang Liu; Taiyong Lv; Junzheng Wang; Jianhua Qin; Santao Ou; Yue Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-07       Impact factor: 9.236

Review 2.  The fibrogenic niche in kidney fibrosis: components and mechanisms.

Authors:  Li Li; Haiyan Fu; Youhua Liu
Journal:  Nat Rev Nephrol       Date:  2022-07-04       Impact factor: 42.439

3.  Tumor necrosis factor-α coordinates with transforming growth factor-β1 to induce epithelial-mesenchymal transition and migration via the NF-κB/NOX4 pathway in bronchial epithelial cells.

Authors:  Ke Li; Rong Zhou; Mingze Ma; Chaomei Jin; Linlin Jiao; Siyu Zhang; Mei Tian; Fang Zhou
Journal:  Mol Biol Rep       Date:  2022-08-01       Impact factor: 2.742

4.  Inhibition of Ubiquitin-specific Protease 4 Attenuates Epithelial-Mesenchymal Transition of Renal Tubular Epithelial Cells via Transforming Growth Factor Beta Receptor Type I.

Authors:  Jin-Yun Pu; Yu Zhang; Li-Xia Wang; Jie Wang; Jian-Hua Zhou
Journal:  Curr Med Sci       Date:  2022-09-30

Review 5.  Signaling pathways of chronic kidney diseases, implications for therapeutics.

Authors:  Qian Yuan; Ben Tang; Chun Zhang
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

6.  Corni Fructus Alleviates UUO-Induced Renal Fibrosis via TGF-β/Smad Signaling.

Authors:  Jin A Lee; Mi-Rae Shin; Seong-Soo Roh
Journal:  Biomed Res Int       Date:  2022-05-06       Impact factor: 3.246

Review 7.  AKI: an increasingly recognized risk factor for CKD development and progression.

Authors:  J T Kurzhagen; S Dellepiane; V Cantaluppi; H Rabb
Journal:  J Nephrol       Date:  2020-07-10       Impact factor: 3.902

8.  Sprr2f protects against renal injury by decreasing the level of reactive oxygen species in female mice.

Authors:  Kieu My Huynh; Anny Chuu-Yun Wong; Bo Wu; Marc Horschman; Hongjuan Zhao; James D Brooks
Journal:  Am J Physiol Renal Physiol       Date:  2020-10-05

9.  Targeting CC chemokine ligand (CCL) 20 by miR-143-5p alleviate lead poisoning-induced renal fibrosis by regulating interstitial fibroblasts excessive proliferation and dysfunction.

Authors:  Lin Han; Yanfang Zou; Chen Yu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

10.  Salvianolic acid B attenuates renal interstitial fibrosis by regulating the HPSE/SDC1 axis.

Authors:  Yang Hu; Man Wang; Yunzheng Pan; Qingju Li; Li Xu
Journal:  Mol Med Rep       Date:  2020-06-15       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.